24.9 Billion Won Invested to Expand Facilities by 4,461m²
Strengthening Production Base for New Drugs and Exports

Jeil Pharmaceutical announced on September 22 that it has completed and received approval for the expansion of the solid dosage building at its Baegam Plant, located in Cheoin-gu, Yongin, Gyeonggi Province.


A total of 24.9 billion won was invested in this expansion project. The company added 4,461 square meters of production facilities to the 3rd and 4th floors of the Baegam Plant, expanding facilities for weighing, mixing, granulation, tableting, coating, sorting, and packaging to increase production of solid oral dosage forms, such as tablets and capsules.


Exterior view of solid dosage manufacturing building at Jeil Pharmaceutical Baegam Plant. Jeil Pharmaceutical

Exterior view of solid dosage manufacturing building at Jeil Pharmaceutical Baegam Plant. Jeil Pharmaceutical

View original image

Once the installation of production equipment is complete, the production capacity of solid oral dosage forms will increase by approximately 71% compared to the previous capacity. Jeil Pharmaceutical plans to secure additional production capacity to meet increased production demand driven by sales growth, while also preparing for business expansion in new drugs and exports.


The company also aims to improve production efficiency and cost competitiveness. The new facilities are equipped with automation systems such as a Building Management System (BMS) and Warehouse Management System (WMS) to boost productivity, increase yield, and reduce manufacturing costs.


The production and quality management infrastructure for global business expansion has also been strengthened. The newly added facilities have been built to comply with domestic and international Good Manufacturing Practice (GMP) standards, and qualification assessments for production support facilities and new equipment are currently underway. These assessments are scheduled to be completed by December 2026, with product-specific validation and license variations planned to begin in the first quarter of 2027.


This production facility expansion is also intended to meet increased production demand resulting from the growing sales of in-house drugs such as 'Zacubo.' Zacubo generated consolidated sales of 64.5 billion won in the first half of this year, an increase of approximately 152% compared to the same period last year.



A Jeil Pharmaceutical official said, "This Baegam Plant expansion is an investment to proactively secure production capacity in anticipation of future sales growth and business expansion in new drugs and exports," adding, "Based on our expanded production capacity and automated production infrastructure, we will further enhance production efficiency and cost competitiveness."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing